ReviewCells2026
Regulated Cell Death in Reproductive Biology: Mechanisms and Therapeutic Opportunities.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulated cell death (RCD) has emerged as a fundamental determinant of cellular homeostasis and tissue remodeling, extending far beyond the classical concept of apoptosis. The identification of emerging RCD pathways, including ferroptosis, pyroptosis, necroptosis, cuproptosis, PANoptosis, and autophagy-dependent cell death, has expanded our understanding of reproductive physiology and disease. RCD mechanisms contribute to reproductive homeostasis and have been increasingly implicated in gametogenesis, folliculogenesis, embryonic development, implantation, placentation, and reproductive aging, while their dysregulation has been associated with infertility, recurrent implantation failure, recurrent pregnancy loss, pregnancy complications, endometriosis, polycystic ovary syndrome (PCOS), gynecological malignancies, and male reproductive disorders. This review provides a comprehensive overview of the molecular mechanisms governing RCD across reproductive physiology and disease, emphasizing the complex interplay between oxidative stress (OS), mitochondrial dysfunction, inflammation, immune regulation, metabolic reprogramming, and genetic and epigenetic networks. Particular attention is given to the contribution of emerging cell death pathways to reproductive disorders and their interactions with environmental and lifestyle factors, including endocrine-disrupting chemicals. In addition, current evidence regarding RCD-associated biomarkers, multi-omics approaches, and therapeutic strategies targeting specific cell death pathways is critically evaluated, with particular emphasis on distinguishing associative molecular signatures from functional evidence of RCD execution. By integrating recent advances from basic, translational, and clinical research, this review highlights the context-dependent role of RCD in reproductive biology and disease and identifies current limitations and future opportunities for RCD-informed diagnostics, patient stratification, and targeted therapeutic interventions in reproductive medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.